A. Koenig

发表

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

C. Tatsuoka, A. Lerner, A. Pieper, 2022, Alzheimer's Research & Therapy.

Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts

D. German, R. Barker, R. Sperling, 2017, The Lancet Neurology.

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study

J. Detre, S. Arnold, D. Wolk, 2017, Alzheimer disease and associated disorders.

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

Steven E. Arnold, Suzanne Craft, David M. Holtzman, 2018, Nature Reviews Neurology.

Cognition in Late-Life Depression: Treatment Considerations

M. Butters, A. Koenig, 2014, Current Treatment Options in Psychiatry.

Cognitive Functioning and Late-Life Depression

M. Butters, Rishi K. Bhalla, A. Koenig, 2014, Journal of the International Neuropsychological Society.

Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.

C. Reynolds, M. Butters, A. Begley, 2014, The Journal of clinical psychiatry.

Neuropsychological functioning in the acute and remitted States of late-life depression.

J. Becker, C. Reynolds, S. Arnold, 2015, Journal of Alzheimer's disease : JAD.

Agitation and Irritability in Alzheimer’s Disease: Evidenced-Based Treatments and the Black-Box Warning

S. Arnold, J. Streim, A. Koenig, 2015, Current Psychiatry Reports.

Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias.

Victoria J. Williams, S. Arnold, Chloe Nobuhara, 2018, Focus.

Outcomes in the Treatment of Major Depressive Disorder

M. Thase, A. Koenig, 2009 .

SAGE‐718 in Patients With Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease: Results From the Phase 2 LUMINARY Study

Sigui Li, K. Paumier, J. Petrillo, 2022, Alzheimer's & Dementia.

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease

J. Trojanowski, L. Shaw, S. Arnold, 2018, PloS one.

Extreme nonresponse to acute phase cognitive therapy for depression: an attempt to replicate and extend.

R. Gallop, M. Thase, R. Jarrett, 2014, Behavior therapy.

First-line pharmacotherapies for depression - what is the best choice?

M. Thase, A. Koenig, 2009, Polskie Archiwum Medycyny Wewnetrznej.

Task-related fMRI BOLD response to hyperinsulinemia in healthy older adults.

Victoria J. Williams, D. Salat, S. Arnold, 2019, JCI insight.